Keywords: gsk, ofatumumab, impresses, cll, trial, uk-based, drug

GSK's ofatumumab impresses in CLL trial

Article | 25 February 2008

Print This

UK-based drug major GlaxoSmithKline says that data from a Phase I/II trial of its anti-CD20 monoclonal antibody, ofatumumab, has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in